Celldex announces completion of enrollment in Phase 2 study of barzolvolimab

Celldex Therapeutics announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria-cold urticaria and symptomatic dermographism. In February 2024, the Company presented positive 12 week primary endpoint results from its ongoing Phase 2 study of barzolvolimab in the most common form of chronic urticaria-chronic spontaneous urticaria. “We are very grateful to all the investigators and patients who supported this trial,” said Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics. “While individuals with inducible urticaria go to great lengths to avoid disease triggers in their daily lives, many find it impossible to do so and are severely burdened by this disease. This is compounded by the fact that there are currently no approved therapies for CIndU other than antihistamines. We believe barzolvolimab holds significant promise as a much needed potential treatment for patients with CIndU and look forward to presenting topline data from this study in the second half of the year.”